Modulation of cytotoxicity of benzamide riboside by expression of NMN adenylyltransferase

Joel A. Yalowitz, Hiremagalur N. Jayaram

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Benzamide riboside (BR) is a nucleoside prodrug that is phosphorylated to its 5′-monophosphate (BRMP) and then converted to its active metabolite, BAD (benzamide adenine dinucleotide), an analogue of NAD by the action of NMN adenylytransferase (NMNAT). BAD is a potent, reversible, and noncompetitive inhibitor of inosine 5′-monophosphate dehydrogenase (IMPDH) resulting in depletion of guanylates (GTP and dGTP). IMPDH inhibitors such as BR induce differentiation and apoptosis as a consequence of GTP depletion. Tiazofurin (TR) and selenazofurin (SR) require similar metabolism by NMNAT. NMNAT is the rate-limiting step in the synthesis of NAD and NAD analogues. BR- and TR-sensitive leukemic cells contain high NMNAT activity, whereas resistant clones have greatly downregulated NMNAT activity (<0.1% of wild type). Perhaps the applicability of BR and analogues could be enhanced if combined with NMNAT gene expression in BR-resistant leukemic blasts. NAD has important regulatory role in repair of DNA damage and cell growth since it is a substrate for poly(ADP-ribose) polymerase (PARP). PARP appears to direct short-patch base excision repair and induce p53 upregulation leading to apoptosis. BR inhibits PARP at high concentrations when assayed in permeabilized leukemic cells. Several other IMPDH inhibitors (TR, mycophenolic acid, and ribavirin) exhibit similar PARP inhibitory activity. Although this inhibition was reversible, it was not prevented by the addition of guanosine, GTP, or its nonhydrolyzable analog γ-S-GTP. Therefore, it can be concluded that IMPDH inhibitors directly inhibit PARP. Presumably, the shared IMP-NAD active site of IMPDH has a similar architecture to the NAD-binding pocket of PARP.

Original languageEnglish
Pages (from-to)749-758
Number of pages10
JournalCurrent Medicinal Chemistry
Volume9
Issue number7
StatePublished - 2002

Fingerprint

Nicotinamide-Nucleotide Adenylyltransferase
IMP Dehydrogenase
Poly(ADP-ribose) Polymerases
Cytotoxicity
tiazofurin
NAD
Modulation
Guanosine Triphosphate
Adenine
Repair
Apoptosis
Mycophenolic Acid
Inosine Monophosphate
Guanosine
Ribavirin
Prodrugs
Cell growth
Metabolites
Nucleosides
Metabolism

Keywords

  • Antimetabolites
  • Apoptosis
  • Cancer chemotherapy
  • Differentiation
  • Growth inhibition
  • GTP

ASJC Scopus subject areas

  • Organic Chemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology

Cite this

Modulation of cytotoxicity of benzamide riboside by expression of NMN adenylyltransferase. / Yalowitz, Joel A.; Jayaram, Hiremagalur N.

In: Current Medicinal Chemistry, Vol. 9, No. 7, 2002, p. 749-758.

Research output: Contribution to journalArticle

Yalowitz, Joel A. ; Jayaram, Hiremagalur N. / Modulation of cytotoxicity of benzamide riboside by expression of NMN adenylyltransferase. In: Current Medicinal Chemistry. 2002 ; Vol. 9, No. 7. pp. 749-758.
@article{07cc56669614471fa3286564aac0a06b,
title = "Modulation of cytotoxicity of benzamide riboside by expression of NMN adenylyltransferase",
abstract = "Benzamide riboside (BR) is a nucleoside prodrug that is phosphorylated to its 5′-monophosphate (BRMP) and then converted to its active metabolite, BAD (benzamide adenine dinucleotide), an analogue of NAD by the action of NMN adenylytransferase (NMNAT). BAD is a potent, reversible, and noncompetitive inhibitor of inosine 5′-monophosphate dehydrogenase (IMPDH) resulting in depletion of guanylates (GTP and dGTP). IMPDH inhibitors such as BR induce differentiation and apoptosis as a consequence of GTP depletion. Tiazofurin (TR) and selenazofurin (SR) require similar metabolism by NMNAT. NMNAT is the rate-limiting step in the synthesis of NAD and NAD analogues. BR- and TR-sensitive leukemic cells contain high NMNAT activity, whereas resistant clones have greatly downregulated NMNAT activity (<0.1{\%} of wild type). Perhaps the applicability of BR and analogues could be enhanced if combined with NMNAT gene expression in BR-resistant leukemic blasts. NAD has important regulatory role in repair of DNA damage and cell growth since it is a substrate for poly(ADP-ribose) polymerase (PARP). PARP appears to direct short-patch base excision repair and induce p53 upregulation leading to apoptosis. BR inhibits PARP at high concentrations when assayed in permeabilized leukemic cells. Several other IMPDH inhibitors (TR, mycophenolic acid, and ribavirin) exhibit similar PARP inhibitory activity. Although this inhibition was reversible, it was not prevented by the addition of guanosine, GTP, or its nonhydrolyzable analog γ-S-GTP. Therefore, it can be concluded that IMPDH inhibitors directly inhibit PARP. Presumably, the shared IMP-NAD active site of IMPDH has a similar architecture to the NAD-binding pocket of PARP.",
keywords = "Antimetabolites, Apoptosis, Cancer chemotherapy, Differentiation, Growth inhibition, GTP",
author = "Yalowitz, {Joel A.} and Jayaram, {Hiremagalur N.}",
year = "2002",
language = "English",
volume = "9",
pages = "749--758",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Modulation of cytotoxicity of benzamide riboside by expression of NMN adenylyltransferase

AU - Yalowitz, Joel A.

AU - Jayaram, Hiremagalur N.

PY - 2002

Y1 - 2002

N2 - Benzamide riboside (BR) is a nucleoside prodrug that is phosphorylated to its 5′-monophosphate (BRMP) and then converted to its active metabolite, BAD (benzamide adenine dinucleotide), an analogue of NAD by the action of NMN adenylytransferase (NMNAT). BAD is a potent, reversible, and noncompetitive inhibitor of inosine 5′-monophosphate dehydrogenase (IMPDH) resulting in depletion of guanylates (GTP and dGTP). IMPDH inhibitors such as BR induce differentiation and apoptosis as a consequence of GTP depletion. Tiazofurin (TR) and selenazofurin (SR) require similar metabolism by NMNAT. NMNAT is the rate-limiting step in the synthesis of NAD and NAD analogues. BR- and TR-sensitive leukemic cells contain high NMNAT activity, whereas resistant clones have greatly downregulated NMNAT activity (<0.1% of wild type). Perhaps the applicability of BR and analogues could be enhanced if combined with NMNAT gene expression in BR-resistant leukemic blasts. NAD has important regulatory role in repair of DNA damage and cell growth since it is a substrate for poly(ADP-ribose) polymerase (PARP). PARP appears to direct short-patch base excision repair and induce p53 upregulation leading to apoptosis. BR inhibits PARP at high concentrations when assayed in permeabilized leukemic cells. Several other IMPDH inhibitors (TR, mycophenolic acid, and ribavirin) exhibit similar PARP inhibitory activity. Although this inhibition was reversible, it was not prevented by the addition of guanosine, GTP, or its nonhydrolyzable analog γ-S-GTP. Therefore, it can be concluded that IMPDH inhibitors directly inhibit PARP. Presumably, the shared IMP-NAD active site of IMPDH has a similar architecture to the NAD-binding pocket of PARP.

AB - Benzamide riboside (BR) is a nucleoside prodrug that is phosphorylated to its 5′-monophosphate (BRMP) and then converted to its active metabolite, BAD (benzamide adenine dinucleotide), an analogue of NAD by the action of NMN adenylytransferase (NMNAT). BAD is a potent, reversible, and noncompetitive inhibitor of inosine 5′-monophosphate dehydrogenase (IMPDH) resulting in depletion of guanylates (GTP and dGTP). IMPDH inhibitors such as BR induce differentiation and apoptosis as a consequence of GTP depletion. Tiazofurin (TR) and selenazofurin (SR) require similar metabolism by NMNAT. NMNAT is the rate-limiting step in the synthesis of NAD and NAD analogues. BR- and TR-sensitive leukemic cells contain high NMNAT activity, whereas resistant clones have greatly downregulated NMNAT activity (<0.1% of wild type). Perhaps the applicability of BR and analogues could be enhanced if combined with NMNAT gene expression in BR-resistant leukemic blasts. NAD has important regulatory role in repair of DNA damage and cell growth since it is a substrate for poly(ADP-ribose) polymerase (PARP). PARP appears to direct short-patch base excision repair and induce p53 upregulation leading to apoptosis. BR inhibits PARP at high concentrations when assayed in permeabilized leukemic cells. Several other IMPDH inhibitors (TR, mycophenolic acid, and ribavirin) exhibit similar PARP inhibitory activity. Although this inhibition was reversible, it was not prevented by the addition of guanosine, GTP, or its nonhydrolyzable analog γ-S-GTP. Therefore, it can be concluded that IMPDH inhibitors directly inhibit PARP. Presumably, the shared IMP-NAD active site of IMPDH has a similar architecture to the NAD-binding pocket of PARP.

KW - Antimetabolites

KW - Apoptosis

KW - Cancer chemotherapy

KW - Differentiation

KW - Growth inhibition

KW - GTP

UR - http://www.scopus.com/inward/record.url?scp=0036244225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036244225&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 749

EP - 758

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 7

ER -